3e:I[185,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SendEmailButton"] 44:I[45269,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SignupCTA"] 3f:T501,

In this episode of On the Edge of Breakthrough: Voices of Cancer Research, Christine Brown, Ph.D., Deputy Director of the T‑Cell Research Laboratory at City of Hope, joins Monty Pal, M.D., F.A.S.C.O., to discuss how years of research in glioblastoma, one of the most aggressive and difficult brain cancers, are helping scientists rethink how CAR T‑cell therapy could effectively treat solid tumors.

Dr. Brown shares lessons learned from treating patients with few options, including how tumors change over time and how the brain’s environment can limit immune‑based treatments.

The conversation explores Brown’s early leadership in delivering CAR T cells directly into the brain, rather than through the bloodstream. The episode delves into her key clinical experiences that revealed both the potential of CAR T‑cell therapy and the challenges of making clinical responses last.

Dr. Brown explains new up and coming approaches designed to improve durability and effectiveness, how these advances could extend beyond cancer to autoimmune diseases. She returns to a simple point: studying how real patients respond—what works, what doesn’t, and why—will shape every next step in her research.